Entera Bio (STU:5DT) Cyclically Adjusted PS Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:5DT Entera Bio Ltd STU:5DT
26 GF Score
Price €2.56
GF Value €0.21
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Entera Bio Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Entera Bio  (STU:5DT) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Entera Bio Cyclically Adjusted PS Ratio Related Terms


Entera Bio Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Entera Bio's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Entera Bio Cyclically Adjusted PS Ratio Chart

Entera Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 87.83 74.50

Entera Bio Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 69.22 69.65 74.50 44.10 71.91

STU:5DT vs CABA, KYTX, SCTX: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Entera Bio's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Entera Bio Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entera Bio's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Entera Bio's Cyclically Adjusted PS Ratio falls into.


STU:5DT
26GF Score
Entera Bio Ltd STU:5DT
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Entera Bio Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Entera Bio's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec25 is calculated as:

For example, Entera Bio's adjusted Revenue per Share data for the fiscal year that ended in Dec25 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec25 (Change)*Current CPI (Dec25)
=0.001/324.0540*324.0540
=0.001

Current CPI (Dec25) = 324.0540.

Entera Bio Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201612 0.000 241.432 0.000
201712 0.000 246.524 0.000
201812 0.053 251.233 0.068
201912 0.017 256.974 0.021
202012 0.017 260.474 0.021
202112 0.018 278.802 0.021
202212 0.004 296.797 0.004
202312 0.000 306.746 0.000
202412 0.004 315.605 0.004
202512 0.001 324.054 0.001

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Entera Bio (STU:5DT) Overvalued in 2026?

Based on GuruFocus' analysis, Entera Bio stock appears to be overvalued. The current stock price of €2.56 is trading 1119% above its estimated GF Value™ of €0.21. GuruFocus considers Entera Bio to be Significantly Overvalued.

Key valuation signals for STU:5DT:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €0.21 vs. price of €2.56 (1119% above fair value)
  • GF Score™: 26/100 with 3 warning signs

No single metric tells the full story. See the STU:5DT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Entera Bio Business Description

Other Exchanges ENTX:USA
Address Kiryat Hadassah, Minrav Building - Fifth Floor, Hadassah Bio Park, Jerusalem, ISR, 9112002
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
26GF Score

Get the complete analysis for STU:5DT

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.56
Price
€0.21
GF Value